Margaux Wooster

Margaux Wooster

Auto-generated profile, based on publicly available information

Margaux Wooster

Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center , New York, NY, 10032

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2021 in Clinical Breast Cancer
Verified
Journal Article
Open access
MWMargaux Wooster
Margaux Wooster
JMJulia E. McGuinness
Julia E. McGuinness
KFKathleen M. Fenn
Kathleen M. Fenn
VSVeena M. Singh
Veena M. Singh
LFLauren E. Franks
Lauren E. Franks
KKKevin Kalinsky
Kevin Kalinsky
Leptomeningeal metastasis (LM) is a devastating complication of metastatic breast cancer; however, diagnosis is limited by low sensitivity of cerebrospinal fluid cytopathology. This study evaluates a novel assay, CNSide™, and demonstrates 100% sensitivity for LM and additionally, capacity for receptor assessment and mutation identification. CNSide™ may be a viable platform to detect LM, with potential use as a diagnostic tool.

22 August 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
MWMargaux Wooster
Margaux Wooster
MMMichael May
Michael May
PAPrashasti Agrawal
Prashasti Agrawal
JLJonathan Lee
Jonathan Lee
BMBenjamin May
Benjamin May
BHBenjamin Herzberg
Benjamin Herzberg
Background: 20% of patients with cancer are estimated to be ineligible for phase III trials because of restrictive eligibility criteria. Ineligibility rates for earlier phase trials are even greater. In response, several groups, including the US Food and Drug Administration, have advocated for more inclusive study designs. We examined Kirsten rat sarcoma virus (KRAS) G12C inhibitor trials to determine if inclusivity has shifted in the development of molecularly targeted therapies. Methods: We evaluated phase I-III studies of KRAS G12C inhibitors in non–small cell lung cancer (NSCLC) by applying criteria from 15 US trials to a multi-institutional real-world cohort of patients with metastatic NSCLC and universal KRAS testing (n = 2383). Eligibility analysis, multivariate logistic regression for ineligibility, and a Cox proportional hazards model were used on patients with KRAS G12C–mutated NSCLC (n = 185) to compare trial enrollment and overall survival under various eligibility modifications. Results: Of patients with metastatic KRAS G12C-mutated NSCLC, 60%-70% were ineligible for any KRAS inhibitor clinical trial, including studies aiming to establish first-line standard of care. Eligibility criteria remained unchanged from phase I to phase III. Performance status, renal function, and active brain metastases were the main causes of trial ineligibility. Liberalizing criteria for renal function and brain metastases increased enrollment by 25% without affecting overall survival (P = .49), whereas allowing worse performance status reduced study effect sizes (P = .001 in second-line and P = .04 in first-line). Conclusions: Most patients with metastatic KRAS G12C-mutated NSCLC are excluded from trials. There is substantial potential to refine trial entry criteria to better balance generalizability, safety, speed, and success.

18 February 2021 in Research Square
Verified
Preprint
Open access
PDF file
MWMargaux Wooster
Margaux Wooster
JMJulia E. McGuinness
Julia E. McGuinness
KFKathleen M. Fenn
Kathleen M. Fenn
VSVeena M. Singh
Veena M. Singh
LFLauren E. Franks
Lauren E. Franks
KKKevin Kalinsky
Kevin Kalinsky
Introduction: Diagnosis of leptomeningeal metastasis (LM) is limited by low sensitivity of cerebrospinal fluid (CSF) cytopathology. Detecting circulating tumor cells (CTCs) in CSF might be more sensitive. We evaluated if TargetSelector™ (TS), a novel assay that captures CTCs in peripheral blood, detects CTCs in CSF.Methods: We enrolled adults with metastatic solid tumors or primary CNS malignancies and clinical suspicion for LM to undergo lumbar puncture (LP) for CSF cytopathology and TS. TS captured CTCs using a primary 10-antibody mixture, streptavidin-coated microfluidic channel, and biotinylated secondary antibodies. CTCs from patients with metastatic breast cancer (MBC) were assessed for estrogen receptor (ER) expression by fluorescent antibody and HER2 amplification by fluorescent in situ hybridization (FISH). CSF cell-free DNA (cfDNA) was extracted for next-generation sequencing (NGS). Results: Fourteen patients, median age 56 years (range, 32-75), underwent diagnostic LP. Primary malignancies were breast (n=10), lung (n=1), colon (n=1), CNS lymphoma (n=1), and glioma (n=1). Among thirteen patients who underwent CSF evaluation by TS, TS had sensitivity of 83% (95% Confidence Interval [CI], 33-100%) and specificity of 86% (95% CI, 42-100%) for LM, defined as positive CSF cytology and/or unequivocal MRI findings. Among MBC patients, concordance of ER and HER2 status between CTCs and metastatic biopsy were 60% and 75%, respectively. NGS of CSF cfDNA identified somatic mutations in three MBC patients, including one with PIK3CAp.H1047L in blood and CSF.Conclusions: TargetSelector™ is a viable platform to detect CSF CTCs, with potential use as a diagnostic tool for LM. Additional, larger studies are warranted.

7 November 2024
Verified
Book Chapter
Closed access
PDF file
MKMatthew Kearney
Matthew Kearney
MWMargaux Wooster
Margaux Wooster
KKKevin Kalinsky
Kevin Kalinsky